Proximal and distal gut hormone secretion in irritable bowel syndrome

被引:49
作者
Van der Veek, PPJ [1 ]
Biemond, I [1 ]
Masclee, AAM [1 ]
机构
[1] Leiden Univ, Ctr Med, Dept Gastroenterol & Hepatol, NL-2300 RC Leiden, Netherlands
关键词
cholecystokinin; irritable bowel syndrome; meal; motilin; peptide YY;
D O I
10.1080/00365520500206210
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. Sensory and motor dysfunctions of the gut are both important characteristics of irritable bowel syndrome (IBS). Several gut peptides contribute to the regulation of gastrointestinal function but little is known about gut hormone secretion in IBS. Material and methods. We evaluated perceptual thresholds and fasting and postprandial plasma levels of proximal (cholecystokinin (CCK), motilin) and distal (peptide YY) gut peptides up to 1 h after ingestion of a high caloric meal in 99 IBS patients and 40 age- and gender-matched healthy controls. Results. Fasting plasma CCK levels were significantly elevated in patients (1.2 +/- 0.8 pM) compared with those in controls (0.8 +/- 0.7 pM, p = 0.006), as was the incremental postprandial CCK response (72 +/- 73 versus 40 +/- 42 pM 60 min, respectively; p = 0.003). No differences in fasting and postprandial motilin or PYY levels were found. The postprandial PYY response was significantly increased in hypersensitive compared to normosensitive patients (215 +/- 135 versus 162 +/- 169 pM, p = 0.048). Patients with a diarrhoea predominant bowel habit had higher fasting motilin levels compared to constipated patients or alternating type IBS patients (82.1 +/- 36.5 versus 60.8 +/- 25.1 versus 57.5 +/- 23.9 pM, one-way ANOVA p = 0.003). Conclusions. IBS patients have increased fasting and postprandial plasma levels of CCK. Changes in plasma levels of motilin and PYY may contribute to the clinical expression of IBS, such as the presence of visceral hypersensitivity or a predominant bowel habit.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 37 条
[1]
ADLER G, 1990, EUR J CLIN INVEST, V20, pS27
[2]
AZPIROZ F, 1985, AM J PHYSIOL, V248, P229
[3]
GUT HORMONE RESPONSES IN THE IRRITABLE BOWEL SYNDROME [J].
BESTERMAN, HS ;
SARSON, DL ;
RAMBAUD, JC ;
STEWART, JS ;
GUERIN, S ;
BLOOM, SR .
DIGESTION, 1981, 21 (04) :219-224
[4]
Chey WY, 2001, AM J GASTROENTEROL, V96, P1499
[5]
New drugs in the management of the irritable bowel syndrome [J].
Farthing, MJG .
DRUGS, 1998, 56 (01) :11-21
[6]
Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? [J].
Gonsalkorale, WM ;
Perrey, C ;
Pravica, V ;
Whorwell, PJ ;
Hutchinson, IV .
GUT, 2003, 52 (01) :91-93
[7]
Evidence for autonomic dysregulation in the irritable bowel syndrome [J].
Gupta, V ;
Sheffield, D ;
Verne, GN .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (08) :1716-1722
[8]
RADIOIMMUNOASSAY OF CHOLECYSTOKININ IN HUMAN-TISSUE AND PLASMA [J].
JANSEN, JBMJ ;
LAMERS, CBHW .
CLINICA CHIMICA ACTA, 1983, 131 (03) :305-316
[9]
The effect of motilin on the rectum in healthy volunteers [J].
Kamerling, IMC ;
Burggraaf, J ;
van Haarst, AD ;
Oppenhuizen-Duinker, MF ;
Schoemaker, HC ;
Biemond, I ;
Jones, R ;
Heinzerling, H ;
Cohen, AF ;
Masclee, AAM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (06) :538-543
[10]
DYSMOTILITY OF THE SMALL-INTESTINE IN IRRITABLE BOWEL SYNDROME [J].
KELLOW, JE ;
PHILLIPS, SF ;
MILLER, LJ ;
ZINSMEISTER, AR .
GUT, 1988, 29 (09) :1236-1243